sFRP-4 levels did not change with creatinine clearance or hyperphosphatemia in CKD or end-stage renal disease patients, and no relation was noted between posttransplant sFRP-4 levels and hypophosphatemia. Conclusions: In CKD, FGF-23 levels rose with decreasing creatinine clearance rates and increasing plasma phosphorus levels, and rapidly decreased post-transplantation suggesting FGF-23 is cleared by the kidney. Residual FGF-23 may contribute to the hypophosphatemia in post-transplant patients.
FGF-23 and sFRP-4 in Chronic Kidney
. The impaired renal function in chronic kidney disease (CKD) is associated with decreased 1,25(OH) 2 D 3 and increased phosphate levels leading to a subsequent elevation in PTH [5] . One of the key goals for CKD therapy is to normalize plasma phosphate since hyperphosphatemia is correlated with significant cardiovascular morbidity and mortality [6] [7] [8] [9] [10] . Therefore, it is critical to understand the relationship between plasma phosphate and the phosphate regulating hormones, 1,25(OH) 2 D 3 and PTH in order to optimize the treatment of CKD patients.
Over the past few years, new phosphate-regulating proteins have been identifi ed that induce phosphaturia by decreasing renal phosphate reabsorption. The two best characterized phosphatonins are fi broblast growth factor-23 (FGF-23) and secreted frizzled related protein-4 (sFRP-4) [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] . In addition to its phosphaturic effects, FGF-23 has also been shown to decrease active vitamin D levels [21] [22] [23] . Athymic nude mice implanted with Chinese hamster ovary cells expressing FGF-23 or injected with recombinant FGF-23 had a reduction in both plasma phosphorus and 1,25(OH) 2 D levels. FGF-23 null mice exhibited hyperphosphatemia and elevated 1,25(OH) 2 D levels [24, 25] . A role in normal phosphate and vitamin D physiology is suggested by the hyperphosphatemia and elevated 1,25(OH) 2 D 3 levels observed in normal adult mice injected with neutralizing antibodies to FGF-23 [26] . Phosphate loading of rats increases FGF-23 levels [27] [28] [29] , but studies in healthy adults have produced mixed effects of dietary phosphate on FGF-23. Escalating phosphate diets were reported to increase [30, 31] or to have no effect [32] on FGF-23 levels in humans.
sFRP-4 is measurable in normal adults. Like FGF-23, sFRP-4 is phosphaturic, and blunts the compensatory increase in 1,25(OH) 2 D 3 in response to hypophosphatemia [33] , but its role in phosphate homeostasis and regulation by phosphate is not clear. A third protein, MEPE (matrix extracellular phosphoglycoprotein) is expressed by phosphate wasting tumors, and has been reported to be phosphaturic [34] , although this remains controversial since MEPE knockout mice do not display altered plasma phosphate levels [35, 36] .
Thus, the phosphatonins are known to cause phosphaturia [12] [13] [14] [15] [16] 33] and are implicated in several hereditary and acquired hypophosphatemic disorders [21, 26, , but their roles in normal physiology or in kidney disease are less well understood. Although FGF-23 levels are detectable in normal individuals [11] and elevated in patients with CKD [32, [55] [56] [57] , it is not known if this change is a consequence of reduced renal clearance and/or elevated phosphorus. If plasma phosphorus concentrations control phosphatonin expression, it is likely that their expression is also altered in other disease entities where phosphate dysregulation is evident. Post-renal transplantation hypophosphatemia is seen commonly, and has clinical importance due to its linkage with post transplant bone disease [58] [59] [60] [61] [62] . The present study examines the impact of hyperphosphatemia and CKD on FGF-23 and sFRP-4, and the potential role of these phosphatonins in post transplantation hypophosphatemia.
Materials and Methods
After approval by the Washington University School of Medicine Human Studies Committee, informed and written consent was taken from 86 patients; 40 were CKD patients not on dialysis, 34 were patients on hemodialysis end-stage renal disease (ESRD) and 12 were pre-renal transplant patients. There were no inclusion or exclusion criteria used in patient recruitment. The CKD patients (n = 40) were 13 females and 27 males. The etiology of their disease was predominantly from hypertension (30%), diabetes (20%), focal segmental glomerulosclerosis (20%), and other glomerular disorders (7.5%). The remaining 22.5% was from miscellaneous causes. A control group was comprised of 12 healthy subjects with normal renal function.
Blood was collected for measurement of plasma levels of phosphorus, calcium, intact PTH, 1,25(OH) 2 [64] . The FGF-23 was measured using a kit that measures the C-terminal fragment of FGF-23 (Immutopics Corporation, San Clemente, Calif., USA). Plasma sFRP-4 measurements were performed using a two-antibody sandwich ELISA as described previously [33] .
In the ESRD population, FRP-4, FGF-23 and plasma phosphorus levels were measured. Six patients were enrolled in a sub-study in which FGF-23 and sFRP-4 were measured when their phosphate binders were temporarily stopped. FGF-23 and sFRP-4 were measured in these patients after their plasma phosphorus rose to greater than 5 mg/dl. These individuals were then placed back on phosphorus binders and FGF-23 and FRP4 were measured again when once their plasma phosphorus fell to less than 4.5 mg/dl.
The patients on the transplant list had blood drawn within one day pre-transplantation and 4-5 days post-transplantation. Plasma FGF-23, sFRP-4, phosphorus, intact PTH and creatinine were measured in these samples. Two patients with delayed graft function were excluded from the study.
Correlations between the levels of FGF-23, sFRP-4 and other blood chemistries were analyzed by ANOVA linear regression and by multivariable regression analysis (GraphPad Instat).
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Results

FGF-23 in Chronic Kidney Disease and End-Stage Renal Disease
Patients with CKD, not on dialysis, had creatinine clearances ranging from 8 to 114 ml/min. The dominant etiologies included hypertension, diabetes and focal segmental glomerulosclerosis. Plasma phosphorus ranged from 2.0 to 6.5 mg/dl and PTH from 11 to 445 pg/ml. The FGF-23 levels in our control population were 67 8 12 RU/ml. In the CKD population, there was a signifi cant inverse relation between creatinine clearance and log FGF-23 levels (r 2 = 0.584, p ! 0.0001) ( fi g. 1 ), although the relationship is curvilinear even when plotted on a semilog scale, suggesting multiple regulatory factors. FGF-23 levels were in the normal range in patients with creatinine clearances greater than 60-70 ml/min. In the ESRD population, all the patients were on hemodialysis from 1 to 16 years. FGF-23 levels in this subset were much higher than the CKD patients ( fi g. 2 ). There was no relation between FGF-23 concentrations and years on dialysis ( fi g. 3 ). . Multiple regression analysis indicated that both creatinine clearance and plasma phosphate independently correlated with FGF-23 levels. As illustrated in fi gure 6 , the increment in FGF-23 with increasing phosphorus is similar when comparing patients grouped by renal function. The slopes for the correlation between FGF-23 and phosphorus are similar for CKD stages 1-3, CKD stages 4-5 and ESRD. However, the regression lines shift upward with decreasing renal function. These fi ndings indicate independent effects of phosphate and renal insuffi ciency on FGF-23 levels.
Most of the CKD patients had secondary hyperparathyroidism and were on phosphate binders and vitamin D analogs. Despite this, a positive correlation was seen between PTH and FGF-23 levels (r 2 = 0.128, p = 0.02) ( fi g. 7 ). There was no correlation between plasma calcium and FGF-23, or between FGF-23 and 1,25(OH) 2 (D) 3 concentrations (data not shown). 
Effect of Modulation of Phosphorus in ESRD Patients
In ESRD patients receiving phosphate binders to control serum phosphorus levels, cessation of binder therapy for 1-2 weeks increased plasma phosphorus and produced a signifi cant increase in FGF-23 levels ( fi g. 8 ). The decrease in plasma phosphorus with reinstatement of phosphate binders was accompanied by a decline in FGF-23 concentrations by 2 weeks in four of the six patients studied, but the reduction did not reach statistical signifi cance ( fi g. 8 ). There were no changes in sFRP-4 in response with binder therapy (data not shown).
FGF-23 in Renal Transplantation
In the transplant patients, two patients had delayed graft function and were excluded from the analysis. In the patients with functioning grafts, plasma creatinine decreased by an average of 76.6% and FGF-23 concentrations declined by 89% ( fi g. 9 a). A 66% reduction in plasma phosphorus was seen in the 10 patients with functioning grafts ( fi g. 9 b). Those patients with post-transplant hypophosphatemia (defi ned as plasma p ^ 2.0 mg/dl) (n = 7) were analyzed further. It should be noted that patients were given phosphorus supplements if their plasma 
sFRP-4 in Renal Disease and Transplantation
In the control group, sFRP-4 levels were 22.3 8 10.5 ng/ml. In patients with CKD, sFRP-4 levels did not correlate with creatinine clearance (r 2 = 0.0026, NS) or with plasma phosphorus (r 2 = 0.046, NS), FGF-23 (r 2 = 0.0097, NS) or calcium (r 2 = 0.0018, NS) ( fi g. 11 ). When patients were stratifi ed according to different stages of CKD, based on kidney disease outcomes quality initiative guidelines, sFRP-4 did not increase with worsening renal function. In stages 4-5 of CKD (creatinine clearance less than 30 ml/min) many patients had sFRP-4 concentrations that fell within the normal range. Additionally, there was no statistical difference in the pre-and post-transplant sFRP-4 concentrations.
Discussion
Secondary hyperparathyroidism is commonly associated with CKD and develops in response to a combination of hypocalcemia, hyperphosphatemia and decreased 1,25(OH) 2 D 3 . The elevated PTH levels drive an increase in renal phosphorus excretion, thereby countering the rising levels of plasma phosphate. Our data show that FGF-23 has a positive correlation with plasma phosphate in CKD and ESRD ( fi gs. [4] [5] [6] , consistent with recruitment of this phosphatonin to aid in phosphate excretion. Studies in experimental animals and in some, but not all, studies in humans indicate that phosphate loading and hyperphosphatemia can increase FGF-23 levels. through inhibition of 1 ␣ -hydroxylase [24] . It is therefore possible that rising FGF-23 levels are responsible for the decline of 1,25(OH) 2 D 3 , and the ensuing hypocalcemia and hyperparathyroidism. Our study, however, could not establish any correlation between FGF-23 levels and 1,25(OH) 2 D levels, likely attributable to the many variables that can infl uence 1,25(OH) 2 D in renal patients.
The functional signifi cance of the correlation between PTH and FGF-23 is not clear. A role for PTH in the regulation of FGF-23 has been suggested by a study demonstrating that parathyroidectomy of uremic rats blocks the increase in FGF-23 in response to a high phosphorus diet, but, curiously, infusion of the uremic rats with PTH could not restore the response, suggesting that perhaps other secreted factors from the parathyroid glands may be involved [65] . Parathyroidectomy has recently been reported to reduce FGF-23 in patients with kidney disease [57] .
Our CKD population spanned all the stages of kidney disease (per kidney disease outcome quality initiative guidelines) and was representative of the most common causes of kidney disease. FGF-23 levels were found to vary inversely with creatinine clearance in CKD with levels rising as kidney disease progressed from stages 1-5 ( fi gs. 1 and 2 ). At a creatinine clearance of more than 60 ml/min, which equates to stages one and two, FGF-23 levels were normal. These fi ndings are in agreement with those in several recently-published studies [55] [56] [57] . FGF-23 is an approximately 26-kDa protein, and so would not be cleared by dialysis. It would be expected then that increasing years on dialysis should lead to accumulation of FGF-23. Although our data showed a trend to for increased FGF-23 levels with years on dialysis, the relationship did not reach signifi cance ( fi g. 3 ) . On the other hand, such this relationship was found to be signifi cant in the recent study of Imanishi et al. [55] using a larger patient population. Our observation that FGF-23 levels fall rapidly following renal transplantation would be consistent with renal clearance of this phosphatonin, but this remains to be directly established. Other mechanisms for FGF-23 turnover are also possible.
The accumulation of FGF-23 with duration of dialysis may be prevented by the medications being used to control phosphate absorption. We found that stopping phosphate binders signifi cantly increased FGF-23 within 2 weeks. Five of six patients showed an increase in FGF-23 when binder administration was halted and plasma phosphorus rose to greater than 5 mg/dl. The mean increase was 55 8 19% (p ! 0.05). Reinstating binder therapy until plasma phosphorus fell to less than 4.5 mg/dl led to a reduction in FGF-23 levels that was not statistically different from either the washout values or from the basal values ( fi g. 8 ). A larger patient population may be necessary to observe these changes, but our results indicate regulation of FGF-23 in dialysis patients. This fi nding is in agreement with the animal data showing regulation of FGF-23 by dietary phosphate [27] [28] [29] , although studies in humans have produced disparate results [30, 32] . It is expected that the impaired phosphate handling in patients with kidney disease would accentuate the effects of phosphate loading.
Renal osteodystrophy seen in CKD persists after kidney transplantation. Post-transplant bone disease has been attributed to a variety of factors, including hyperparathyroidism, pre-transplant bone disease, steroids, immunosuppressive medications and hypophosphatemia [58] [59] [60] [61] .
Hypophosphatemia is often observed following renal transplantation; its etiology is attributed to PTH-dependent and independent mechanisms. The PTH-independent mechanisms have been ascribed to corticosteroids, cyclosporine, and tubular dysfunction. Green et al. [61] demonstrated the presence of an unknown humoral factor in the plasma of transplanted patients, which leads to decreased NaPi activity in OK cells. We hypothesized that the large amount of FGF-23 that accumulates pretransplantation is not cleared immediately post transplantation, and may drive the phosphate leak. Our results showed that all transplanted patients with good renal function (plasma creatinine less than 2.0 mg/dl), became hypophosphatemic. The hypophosphatemia was seen as early as 2 or 3 days post-transplant, and many of these patients were on phosphate supplements by the time their FGF-23 was measured on the 5th post-transplant day. After transplantation, there was an 89 and 64% drop in the FGF-23 and phosphorus levels, respectively ( fi g. 9 a and b). Post-transplantation hypophosphatemia (plasma p ! 2 mg/dl) correlated inversely with FGF-23 levels ( fi g. 10 a), indicating that elevated FGF-23 likely contributes to the post-transplant hypophosphatemia. Other factors, including PTH, may also be involved, although we did not observe a correlation of PTH with post-transplantation phosphorus levels in our study ( fi g. 10 b).
sFRP-4 belongs to a family of soluble proteins that have a frizzled-like cysteine-rich domain and function as modulators of Wnt-Fz signals. Recent studies have shown that sFRP-4 is a phosphatonin [16, 33] . Infusion of recombinant sFRP-4 led to phosphaturia in rats, but did not produce an expected rise in 1,25(OH) 2 D 3 levels [33] .
sFRP-4 is phosphaturic, but its role in phosphate homeostasis is unclear. We were unable to demonstrate any relationship between plasma sFRP-4 levels and plasma phosphate, and, unlike FGF-23, sFRP-4 did not increase with progressive renal failure, suggesting that sFRP-4 is not cleared by the kidney. Modulating plasma phosphate by ceasing and reinstating phosphate binders also did not alter sFRP-4. Further studies will be required to determine the factors that regulate sFRP-4.
In conclusion, plasma FGF-23 appears to be cleared by the kidney, with levels increasing with progressive renal failure. However, the lack of correlation with years on dialysis would indicate a complex control of FGF-23 synthesis and degradation. Our fi ndings show a correlation of FGF-23 with plasma phosphate in patients with kidney disease and an elevation in FGF-23 when phosphate levels are allowed to increase by withdrawal of phosphate binders, supporting the notion that FGF-23 plays a key role in phosphate homeostasis. Recovery of renal function post-transplantation leads to a rapid clearance of the FGF-23, but correlation with plasma phosphate suggests that residual FGF-23 may contribute to the post-transplant hypophosphatemia and bone disease.
